Search results
Showing 1 to 15 of 185 results for oedema
Evidence-based recommendations on brolucizumab (Beovu) for diabetic macular oedema in adults.
Evidence-based recommendations on faricimab (Vabysmo) for diabetic macular oedema in adults.
Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema in adults.
View recommendations for TA274Show all sections
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating visual impairment caused by diabetic macular oedema in adults.
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)
Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for visual impairment caused by chronic diabetic macular oedema that has not responded well enough to available treatments in adults.
Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by diabetic macular oedema in adults.
Evidence-based recommendations on faricimab (Vabysmo) for treating visual impairment caused by macular oedema after retinal vein occlusion in adults.
Evidence-based recommendations on ranibizumab (Lucentis) for treating visual impairment caused by macular oedema secondary to retinal vein occlusion in adults.
Aflibercept for untreated diabetic macular oedema [TSID10621]
Topic prioritisation
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating macular oedema following retinal vein occlusion in adults.
Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion.
Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by macular oedema from central retinal vein occlusion in adults.
This guideline covers managing and monitoring diabetic retinopathy in people under the care of hospital eye services. This includes non-proliferative and proliferative diabetic retinopathy, and diabetic macular oedema.
This guideline covers the general principles for managing intravenous (IV) fluid therapy in hospital inpatients aged 16 and over with a range of conditions. It aims to help prescribers understand the optimal amount and composition of IV fluids to be administered and the best rate at which to give them, to improve fluid prescribing and outcomes among people in hospital. It does not cover pregnant women, and those with severe liver or renal disease, diabetes or burns.
This guideline covers managing cataracts in adults aged 18 and over. It aims to improve care before, during and after cataract surgery by optimising service organisation, referral and surgical management, and reducing complications. It further aims to improve the availability of information for people with cataracts before, during and after cataract surgery.